Pharmacogenetic assessment of clinical outcome in patients with metastatic breast cancer treated with docetaxel plus capecitabine.

ABSTRACT:

Purpose

Docetaxel plus capecitabine, a commonly used chemotherapeutic regimen for metastatic breast cancer (MBC), is highly variable in its effectiveness. We aimed to investigate whether allelic variants of cytochrome P450 (CYP450) affected objective response, progression-free survival (PFS), and overall survival (OS) in MBC.

Patients and methods

79 SNPs in CYP450, whose minor allele frequency were ≥ 10%, were genotyped in 69 MBC patients who were treated with docetaxel plus capecitabine. Pearson's χ(2) test or Fisher's exact test was used to investigate the influence of SNPs on objective response as appropriate. Log-rank test was used to assess the association between SNPs and survival outcomes.

Results

There is no significant association between polymorphisms and bo

SUBMITTER: Dong N 

PROVIDER: S-EPMC11824232 | biostudies-literature | 2012 Jul

REPOSITORIES: biostudies-literature